- AI-screener
- Securities US
- Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited
$17.72
$0.52
3.01%
6 Jun 20:00
$12.47
$22.80
52 weeks low/high
Technical analysis
- Trend ClassTurning down
- Trend PowerAlmost flat
- PatternAscending wedge
- EMA-20Bullish reversalThe price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.
- EMA-50Bullish reversal2025-04-29 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.
- EMA-100Bullish reversal2025-05-07 the price crossed up the moving average line and getting closer to the MA, which means that the short-term upside trend weakens.
- StochasticBearishThe stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.
- RSIBullish RecoveryRSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.
- MACDBearish reversalOscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.
- Candle pattern typeBearish Three Outside DownPattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second day body engulfs the white body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -3.30% | 2.64% | $17.34 | $17.83 | 148.32M |
| Week | 2.40% | 3.10% | $16.52 | $17.87 | 1.07B |
| Month | -2.37% | 0.45% | $16.39 | $18.30 | 4.10B |
| 3 Months | 11.72% | 0.82% | $12.47 | $18.30 | 9.93B |
| 6 Months | -0.85% | 16.34% | $12.47 | $22.80 | 19.99B |
| Year | 2.16% | 0.64% | $12.47 | $22.80 | 33.05B |
| 3 years | 92.52% | 75.95% | $6.78 | $22.80 | 79.50B |
| 5 years | 33.93% | 100.06% | $6.78 | $22.80 | 119.15B |
| All time | 190.34% | 81.24% | $5.84 | $72.31 | 115.03B |
Volatility
| TEVA | By industry | |
|---|---|---|
| Yesterday | 15.80% | 1.28% |
| Week | 3.37% | 7.29% |
| Month | 6.32% | 10.86% |
| 3 Months | 16.16% | 20.88% |
| 6 Months | 21.52% | 29.79% |
| Year | 48.41% | 39.37% |
| 3 years | 77.96% | 85.40% |
| 5 years | 97.94% | 115.71% |
| All time | — | — |
- Sortino
- -0.01
- Sharpe
- -0.01
- Sterling
- -0.01
- Liquidity index
- 6.34
- Alpha
- 0.00131
- Beta
- 1.09
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$20.38B
Capitalization
1.15B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US8816242098
ISIN
100
Lot size
Mr. Richard D. Francis
CEO
Website
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.